84 related articles for article (PubMed ID: 20211188)
1. Nonantibiotic properties of tetracyclines: structural basis for inhibition of secretory phospholipase A2.
Dalm D; Palm GJ; Aleksandrov A; Simonson T; Hinrichs W
J Mol Biol; 2010 Apr; 398(1):83-96. PubMed ID: 20211188
[TBL] [Abstract][Full Text] [Related]
2. Design of specific peptide inhibitors for group I phospholipase A2: structure of a complex formed between phospholipase A2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 A resolution reveals unique features.
Singh RK; Vikram P; Makker J; Jabeen T; Sharma S; Dey S; Kaur P; Srinivasan A; Singh TP
Biochemistry; 2003 Oct; 42(40):11701-6. PubMed ID: 14529280
[TBL] [Abstract][Full Text] [Related]
3. Predicted three-dimensional structural models of venom serine protease inhibitors and their interactions with trypsin and chymotrypsin.
Azim MK; Grossmann JG; Zaidi ZH
J Nat Toxins; 1999 Oct; 8(3):363-84. PubMed ID: 10591040
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a novel phospholipase A2 from crude venom of Indian cobra sub-species Naja naja sagittifera at 1.48 angstoms resolution.
Singh RK; Jabeen T; Sharma S; Kaur P; Srinivasan A; Singh TP
Indian J Biochem Biophys; 2005 Oct; 42(5):279-86. PubMed ID: 23923535
[TBL] [Abstract][Full Text] [Related]
5. Mutations on the N-terminal region abolish differentially the enzymatic activity, membrane-damaging activity and cytotoxicity of Taiwan cobra phospholipase A2.
Chiou YL; Cheng YC; Kao PH; Wang JJ; Chang LS
Toxicon; 2008 Feb; 51(2):270-9. PubMed ID: 18022206
[TBL] [Abstract][Full Text] [Related]
6. Mutations on N-terminal region of Taiwan cobra phospholipase A(2) result in structurally distorted effects.
Chiou YL; Lin SR; Chang LS
J Pept Sci; 2008 Aug; 14(8):890-7. PubMed ID: 18288787
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution.
Jabeen T; Singh N; Singh RK; Sharma S; Somvanshi RK; Dey S; Singh TP
Acta Crystallogr D Biol Crystallogr; 2005 Dec; 61(Pt 12):1579-86. PubMed ID: 16301791
[TBL] [Abstract][Full Text] [Related]
8. Recognition of drug degradation products by target proteins: isotetracycline binding to Tet repressor.
Volkers G; Petruschka L; Hinrichs W
J Med Chem; 2011 Jul; 54(14):5108-15. PubMed ID: 21699184
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence single-molecule study of cobra phospholipase A2 action on a supported gel-phase lipid bilayer.
Chiu CR; Huang WN; Wu WG; Yang TS
Chemphyschem; 2009 Feb; 10(3):549-58. PubMed ID: 19142925
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals the presence of the new common ligand-binding site.
Singh N; Kumar RP; Kumar S; Sharma S; Mir R; Kaur P; Srinivasan A; Singh TP
J Mol Recognit; 2009; 22(6):437-45. PubMed ID: 19462410
[TBL] [Abstract][Full Text] [Related]
11. Surface pressure-dependent interactions of secretory phospholipase A2 with zwitterionic phospholipid membranes.
Huang WN; Chen YH; Chen CL; Wu W
Langmuir; 2011 Jun; 27(11):7034-41. PubMed ID: 21557547
[TBL] [Abstract][Full Text] [Related]
12. Structural difference between group I and group II cobra cardiotoxins: X-ray, NMR, and CD analysis of the effect of cis-proline conformation on three-fingered toxins.
Chen TS; Chung FY; Tjong SC; Goh KS; Huang WN; Chien KY; Wu PL; Lin HC; Chen CJ; Wu WG
Biochemistry; 2005 May; 44(20):7414-26. PubMed ID: 15895985
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling of the additional inhibitor site located in secretory phospholipase A(2).
Ompraba G; Velmurugan D; Louis PA; Rafi ZA
J Biomol Struct Dyn; 2010 Feb; 27(4):489-500. PubMed ID: 19916570
[TBL] [Abstract][Full Text] [Related]
14. Structural changes and binding characteristics of the tetracycline-repressor binding site on induction.
Lanig H; Othersen OG; Seidel U; Beierlein FR; Exner TE; Clark T
J Med Chem; 2006 Jun; 49(12):3444-7. PubMed ID: 16759085
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the tet repressor in complex with a novel tetracycline, 9-(N,N-dimethylglycylamido)- 6-demethyl-6-deoxy-tetracycline.
Orth P; Schnappinger D; Sum PE; Ellestad GA; Hillen W; Saenger W; Hinrichs W
J Mol Biol; 1999 Jan; 285(2):455-61. PubMed ID: 9878420
[TBL] [Abstract][Full Text] [Related]
16. The structural and functional contribution of N-terminal region and His-47 on Taiwan cobra phospholipase A2.
Kao PH; Chen KC; Lin SR; Chang LS
J Pept Sci; 2008 Mar; 14(3):342-8. PubMed ID: 18008383
[TBL] [Abstract][Full Text] [Related]
17. A new type of thrombin inhibitor, noncytotoxic phospholipase A2, from the Naja haje cobra venom.
Osipov AV; Filkin SY; Makarova YV; Tsetlin VI; Utkin YN
Toxicon; 2010; 55(2-3):186-94. PubMed ID: 19622365
[TBL] [Abstract][Full Text] [Related]
18. Understanding the structural basis for substrate and inhibitor recognition in eukaryotic GH11 xylanases.
Vardakou M; Dumon C; Murray JW; Christakopoulos P; Weiner DP; Juge N; Lewis RJ; Gilbert HJ; Flint JE
J Mol Biol; 2008 Feb; 375(5):1293-305. PubMed ID: 18078955
[TBL] [Abstract][Full Text] [Related]
19. Phospholipase A2 as a target protein for nonsteroidal anti-inflammatory drugs (NSAIDS): crystal structure of the complex formed between phospholipase A2 and oxyphenbutazone at 1.6 A resolution.
Singh N; Jabeen T; Somvanshi RK; Sharma S; Dey S; Singh TP
Biochemistry; 2004 Nov; 43(46):14577-83. PubMed ID: 15544328
[TBL] [Abstract][Full Text] [Related]
20. Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
Thwin MM; Satyanarayanajois SD; Nagarajarao LM; Sato K; Arjunan P; Ramapatna SL; Kumar PV; Gopalakrishnakone P
J Med Chem; 2007 Nov; 50(24):5938-50. PubMed ID: 17973469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
